CPTAC expertise has been charged to develop RAS specific targeted proteomic assays to study the important pathways of human cancer.
The oncogene RAS is linked to 30 percent of human cancers, but the search for a targeted therapy for RAS has remained elusive. To advance our understanding of this oncogene and to develop improved targeted therapies against RAS pathway, the National Cancer Institute (NCI) has launched a RAS Initiative.
One key aspect of the initiative is the use of robust proteomic technologies to quantitatively measure proteins in the RAS pathway. For this effort, expertise from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) is being utilized for the development of quantitative Multiple Reaction Monitoring Mass Spectrometry (MRM-MS)-based multiplexed assays against RAS protein/peptide targets of interest.
Assays, reagents and SOPs developed by the awardees will be provided to the public as a community resource to enable studies by cancer researchers in unraveling the oncogenic role of the RAS proteins in many cancers. Click here to find out more information about this project and click here to read more about how targeted proteomics is being utilized.
Recently, CPTAC-Leidos awarded contracts to the following investigators:
Amanda Paulovich, MD, PhD
Associated Member, Clinical Research Division; Director, Early Detection Initiative; Fred Hutchinson Cancer Research Center
Member; Fred Hutchinson/University of Washington Cancer Consortium
Associate Professor, Department of Medicine/Division of Oncology; Associate Faculty Member, Molecular and Cellular Biology Program; University of Washington
Steven A. Carr, PhD
Director of Proteomics; Broad Institute of MIT and Harvard
John Koomen, PhD
Associate Member, Moffitt Cancer Center